Write a request to waive a specific FDA regulatory requirement

How do you write a request to waive an FDA regulatory requirement?

Name the precise applicable requirement, application and proposed departure, then identify the authority that permits the request. Explain why compliance is unnecessary or cannot be achieved, how an alternative meets the requirement’s purpose, or the other supported justification. Address the relevant risks and preserve FDA’s actual decision; a general waiver letter does not waive unrelated or statutory obligations.

Before you begin

General administrative waiver preparation under the applicable regulatory authority; specialized pediatric, bioavailability and informed-consent questions require their own analysis.

What you will prepare: A precise request with a supported legal basis, alternative and risk rationale.

Identify exactly what FDA is being asked to waive

Quote or accurately identify the specific requirement, governing part, application, affected activity and requested duration. Explain why it applies before arguing for relief. “Waive additional studies” is too ambiguous to establish an authority or a review standard.

For an IND, 312.10 describes a request addressing why compliance is unnecessary or cannot be achieved, an alternative satisfying the purpose, or other justification; FDA's decision also considers risk to subjects. Part 314 has a separate waiver provision. Do not turn either into a universal power to waive statutory requirements or requirements in another regulatory part. If the request is for a pediatric waiver or in-vivo BA/BE evidence, use the dedicated analysis and heading.

Explain the alternative in operational terms

Prepare a two-column comparison of the ordinary requirement and the proposed approach. For each difference, state the purpose served by the original requirement, the evidence supplied by the alternative, risks or information gaps and mitigation. Name the people who can provide the supporting records.

An editorial outline is: scope and authority; factual circumstances; requested relief; alternative submission or activity; evidence of adequacy; limitations and safeguards; timing; attachments; requested agency action. Where the request rests on inability to comply, explain the attempts and constraints. A deadline or budget preference alone is not a completed rationale.

Preserve the decision rather than assuming acceptance

Track the submitted request, any questions, actual FDA response and conditions. Until the applicable decision or procedure establishes relief, do not mark the underlying requirement as waived. Cross-reference the decision wherever the dossier would otherwise appear to lack required evidence.

Fictional editorial exercise: a team asks to change an annual-report schedule, but its template cites an unrelated pediatric-study waiver. Identify the actual reporting provision and requested scheduling change, then build the rationale under the correct authority. If the application pathway is missing, the writer can assemble timing facts but cannot select the governing waiver route.

Check the authority before arguing for the alternative

The two general provisions discussed here have defined scopes. Establish which requirement applies before selecting one.

Use a comparison record for the proposed departure: ordinary requirement; purpose; alternative; evidence supplied; information lost; mitigation; and limits of the request. If the alternative has a gap, say what it is and why the proposal remains justified. A comparison that lists only advantages cannot support a balanced review.

Scope exercise: the project asks to change one reporting arrangement but the draft seeks relief from “all reporting requirements.” Narrow the request to the actual provision, period and proposed alternative. Identify related obligations that remain applicable. The broader wording would ask FDA to resolve a different question from the one the evidence addresses.

For an IND, §312.10(b) requires FDA to find that noncompliance would not pose a significant and unreasonable risk to subjects, alongside the relevant justification. Connect the scientific and operational evidence to that boundary. For an NDA, do not copy the IND provision as though the same text controls every Part 314 request. Neither provision establishes universal authority over other regulatory parts.

Track the submitted version, any FDA questions, response and conditions. If relief is limited to a specified period or alternative, carry that limitation into the affected dossier section. A granted waiver should explain an otherwise apparent omission; an ungranted request should remain visibly pending.

Use the dedicated pediatric waiver guide or bioavailability/bioequivalence waiver guide when those are the actual tasks. Planned emergency research belongs with the EFIC guide, not a generic IND waiver template.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides